Wikidata

(Q64806738)

English

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

clinical trial

In more languages

Statements

short name
LemKids (English)
0 references
title
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT) (English)
0 references
medical condition
multiple sclerosis
0 references
sclerosis
0 references
country
Austria
0 references
Belgium
0 references
Bulgaria
0 references
France
0 references
Greece
0 references
Italy
0 references
Netherlands
0 references
Norway
0 references
Poland
0 references
Portugal
0 references
Spain
0 references
Switzerland
0 references
Turkey
0 references
United Kingdom
0 references
start time
24 October 2017
0 references
end time
July 2026
0 references
number of participants
50
0 references
minimum age
10 year
0 references
maximum age
17 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64806738&oldid=2155077324"